S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   443.97 (-0.19%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:ALGS

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

$0.98
+0.00 (+0.10%)
(As of 04:00 PM ET)
Today's Range
$0.92
$1.00
50-Day Range
$0.64
$1.13
52-Week Range
$0.54
$1.38
Volume
312,472 shs
Average Volume
365,578 shs
Market Capitalization
$74.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aligos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.47mentions of Aligos Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.83) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.87 out of 5 stars

Medical Sector

549th out of 938 stocks

Biological Products, Except Diagnostic Industry

91st out of 154 stocks

ALGS stock logo

About Aligos Therapeutics Stock (NASDAQ:ALGS)

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ALGS Stock Price History

ALGS Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Aligos Therapeutics Inc (ALGS)
Recap: Aligos Therapeutics Q4 Earnings
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Tracking Baker Brothers Portfolio - Q4 2023 Update
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics Inc Ordinary Shares
See More Headlines
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALGS
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-87,680,000.00
Net Margins
-607.03%
Pretax Margin
-559.49%

Debt

Sales & Book Value

Annual Sales
$15.53 million
Book Value
$1.23 per share

Miscellaneous

Free Float
63,184,000
Market Cap
$73.07 million
Optionable
Optionable
Beta
2.34
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Lawrence M. Blatt MBA (Age 62)
    Ph.D., CEO, President & Chairman of the Board
    Comp: $832.73k
  • Dr. Julian A. Symons DPHIL (Age 62)
    Executive VP & Chief Scientific Officer
    Comp: $618.66k
  • Ms. Lesley Ann Calhoun CPA (Age 58)
    Executive VP & CFO
  • Kristina Engeseth
    VP and Head of People & Culture
  • Dr. Matthew W. McClure M.D. (Age 52)
    Executive VP & Chief Medical Officer
  • Dr. Sushmita M. Chanda DABT (Age 57)
    Ph.D., Executive Vice President of Translational Safety Sciences
  • Dr. David B. Smith Ph.D.
    Executive VP & Head of Chemical Operations
  • Dr. Tse-I Lin Ph.D.
    VP of Early Compound Development & Belgian Site Head

ALGS Stock Analysis - Frequently Asked Questions

How have ALGS shares performed in 2024?

Aligos Therapeutics' stock was trading at $0.6640 at the beginning of the year. Since then, ALGS stock has increased by 45.4% and is now trading at $0.9656.
View the best growth stocks for 2024 here
.

When is Aligos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALGS earnings forecast
.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.03. The firm had revenue of $1.54 million for the quarter. Aligos Therapeutics had a negative net margin of 607.03% and a negative trailing twelve-month return on equity of 116.41%.

When did Aligos Therapeutics IPO?

Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

Who are Aligos Therapeutics' major shareholders?

Aligos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.12%), Altitude Crest Partners Inc. (3.80%), Hhlr Advisors LTD. (2.54%), Opaleye Management Inc. (1.73%), Newtyn Management LLC (1.67%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALGS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners